UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

Clinical lymphoma, myeloma and leukemia, 2021-04, Vol.21 (4), p.230-237.e12

2021

Volltextzugriff (PDF)

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Hematological oncology, 2023-06, Vol.41 (S2), p.131-132

2023

Volltextzugriff (PDF)

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

The New England journal of medicine, 2018-03, Vol.378 (12), p.1107-1120

2018

Volltextzugriff (PDF)

DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS

Hematological oncology, 2019-06, Vol.37 (S2), p.128-128

2019

Volltextzugriff (PDF)

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.408-410

2017

Volltextzugriff (PDF)

INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

Hematological oncology, 2017-06, Vol.35 (S2), p.24-25

2017

Volltextzugriff (PDF)

BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE

Hematological oncology, 2017-06, Vol.35 (S2), p.36-37

2017

Volltextzugriff (PDF)

PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.54-54

2017

Volltextzugriff (PDF)

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

Hematological oncology, 2017-06, Vol.35 (S2), p.229-230

2017

Volltextzugriff (PDF)

A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.265-266

2017

Volltextzugriff (PDF)

Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages

Science (American Association for the Advancement of Science), 1994-03, Vol.263 (5153), p.1612-1615

1994

Volltextzugriff (PDF)

Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4

Annals of oncology, 2017-09, Vol.28, p.v368-v368

2017

Volltextzugriff (PDF)

611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies

European journal of cancer supplements, 2010, Vol.8 (7), p.192-192

2010

Volltextzugriff (PDF)

Parallel Phase I Studies of Two Schedules of Bkm120 Plus Carboplatin and Paclitaxel for Patients with Advanced Solid Tumors

Annals of oncology, 2014-09, Vol.25, p.iv156

2014

Volltextzugriff (PDF)

469PPARALLEL PHASE I STUDIES OF TWO SCHEDULES OF BKM120 PLUS CARBOPLATIN AND PACLITAXEL FOR PATIENTS WITH ADVANCED SOLID TUMORS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv156-iv156

2014

Volltextzugriff (PDF)

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological oncology, 2017-06, Vol.35, p.408-410

2017

Volltextzugriff (PDF)

Allergic reaction to varicella vaccine

Annals of internal medicine, 1997-05, Vol.126 (10), p.833

1997

Volltextzugriff (PDF)

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

Blood, 2009-11, Vol.114 (22), p.1673-1673

2009

Volltextzugriff (PDF)

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3003-3003

2011

Volltextzugriff (PDF)

AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2591-2591

2011

Volltextzugriff (PDF)

A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8578-8578

2009

Volltextzugriff (PDF)

Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e19554-e19554

2009

Volltextzugriff (PDF)

VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)

Hematological oncology, 2017-06, Vol.35 (S2), p.203-204

2017

Volltextzugriff (PDF)

A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8511-8511

2008

Volltextzugriff (PDF)

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.8512-8512

2008

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(113)
Buchkapitel
(1)

Sprache

Englisch
(114)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Humans
(30)
Female
(23)
Adult
(21)
Aged
(21)
Male
(21)
Middle Aged
(21)
Oncology
(17)
Lymphoma
(15)
Hematology
(14)
Patients
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Animals
(9)
Aged, 80 And Over
(8)
Mice
(8)
Prognosis
(8)
Rituximab
(8)
Targeted Cancer Therapy
(8)
Treatment Outcome
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS

BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE

PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages

Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4

611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies

Parallel Phase I Studies of Two Schedules of Bkm120 Plus Carboplatin and Paclitaxel for Patients with Advanced Solid Tumors

469PPARALLEL PHASE I STUDIES OF TWO SCHEDULES OF BKM120 PLUS CARBOPLATIN AND PACLITAXEL FOR PATIENTS WITH ADVANCED SOLID TUMORS

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

Allergic reaction to varicella vaccine

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study

AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors

A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)

Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma

VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)

A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies

A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas

Suchergebnisse filtern